首页 > 最新文献

Kidney international. Supplement最新文献

英文 中文
Alport syndrome. Alport综合征。
Pub Date : 2012-01-01 DOI: 10.1007/978-3-642-02202-9_295
C. Kashtan
{"title":"Alport syndrome.","authors":"C. Kashtan","doi":"10.1007/978-3-642-02202-9_295","DOIUrl":"https://doi.org/10.1007/978-3-642-02202-9_295","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74711594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
New strategies to prevent cardiovascular risk in chronic kidney disease. Proceedings of the Sixth International Conference on Hypertension and the Kidney. February 2008. Madrid, Spain. 预防慢性肾脏疾病心血管风险的新策略。第六届高血压与肾脏国际会议论文集。2008年2月。马德里,西班牙。
Pub Date : 2008-12-01
{"title":"New strategies to prevent cardiovascular risk in chronic kidney disease. Proceedings of the Sixth International Conference on Hypertension and the Kidney. February 2008. Madrid, Spain.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28023735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of Renal Disease in the Emerging World: Toward Global Health Equity. Proceedings of the Bellagio Conference, March 16-18, 2004, Italy. 新兴世界的肾脏疾病预防:迈向全球健康公平。Bellagio会议论文集,2004年3月16-18日,意大利。
Pub Date : 2005-09-01
{"title":"Prevention of Renal Disease in the Emerging World: Toward Global Health Equity. Proceedings of the Bellagio Conference, March 16-18, 2004, Italy.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25751900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid. 25 mmol/L碳酸氢盐/10 mmol/L乳酸缓冲腹膜透析液的体外生物相容性
Pub Date : 2003-12-01
Line Skoufos, Nicholas Topley, Laurinda Cooker, Anne Dawnay, David J Millar, Clifford J Holmes, Dirk Faict

Unlabelled: The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.

Background: The biocompatibility profile of a new peritoneal dialysis (PD) solution (Physioneal 35) was determined using a selection of in vitro assay systems. Physioneal 35 is buffered by a combination of 25 mmol/L bicarbonate and 10 mmol/L lactate, thereby providing a solution with a total of 35 mmol/L of alkali to complement the currently available 25 mmol/L bicarbonate and 15 mmol/L lactate combination solution, Physioneal 40. In addition, the new solution contains a calcium concentration of 1.75 mmol/L rather than 1.25 mmol/L present in Physioneal 40. Physioneal 35 and 40 are manufactured in double chamber bag systems that permit separation of glucose from the buffer during sterilization. When the two chambers are mixed just before patient use, the resulting solution has a neutral pH and reduced glucose degradation content. Physioneal 35 was evaluated for its cytotoxicity potential using a murine fibroblast assay, its acute effect on human neutrophil and human peritoneal mesothelial cell function, and its in vitro potential to form advanced glycation end products (AGE). The biocompatibility characteristics of this new formulation were compared with that of a conventional, lactate-based solution and to that of its parent formulation, Physioneal 40.

Methods: Proliferation of murine fibroblasts was determined after exposure to dialysis fluids for 72 hours. Cell viability was assayed by the ability to take up neutral red dye. Human neutrophils were exposed for 15 minutes to dialysis fluids, and their ATP content and phorbol 12-myristate 13-acetate (PMA) stimulated chemiluminescence response was determined as a measure of viability and respiratory burst activity, respectively. Cellular interleukin (IL)-1beta-driven IL-8 synthesis by human mesothelial cells following acute exposure to dialysis fluids was also assessed. Advanced glycation end product formation in the dialysis fluids was measured after 5 and 20 days of incubation with human serum albumin (HSA) as the model protein.

Results: In all assays employed, the biocompatibility profile of Physioneal 35 was similar to that of the Physioneal 40 parent formulation. Physioneal 35 showed a significant improvement in biocompatibility performance compared to a pH neutralized conventional lactate-buffered peritoneal dialysis solution in the murine fibroblast assay. In the acute exposure assays, human neutrophil viability and respiratory burst were significantly improved compared with the acidic, conventional solution; however, no statistically significant improvement were seen in mesothelial cells. AGE formation, which is thought to be an important mechanism by which glucose and glucose degradation products cause structural and functional changes of the peritoneal membrane, was si

未标记:25 mmol/L碳酸氢盐/10 mmol/L乳酸缓冲腹膜透析液的体外生物相容性性能。背景:一种新的腹膜透析(PD)溶液(Physioneal 35)的生物相容性特征是通过选择体外检测系统来确定的。Physioneal 35由25 mmol/L碳酸氢盐和10 mmol/L乳酸的混合物缓冲,从而提供一种总共含有35 mmol/L碱的溶液,以补充目前可用的25 mmol/L碳酸氢盐和15 mmol/L乳酸的组合溶液Physioneal 40。此外,新溶液中的钙浓度为1.75 mmol/L,而不是Physioneal 40中的1.25 mmol/L。Physioneal 35和40是在双室袋式系统中制造的,允许在灭菌期间从缓冲液中分离葡萄糖。在患者使用前将两个腔混合,得到的溶液pH值为中性,葡萄糖降解含量降低。通过小鼠成纤维细胞试验评估了Physioneal 35的细胞毒性潜力,对人中性粒细胞和人腹膜间皮细胞功能的急性影响,以及其在体外形成晚期糖基化终产物(AGE)的潜力。将该新制剂的生物相容性与传统的乳酸基溶液及其母体制剂Physioneal 40进行了比较。方法:观察透析液作用72小时后小鼠成纤维细胞的增殖情况。通过对中性红色染料的吸收能力测定细胞活力。将人中性粒细胞暴露于透析液中15分钟,分别测定其ATP含量和phorbol 12-肉豆酸酯13-乙酸酯(PMA)刺激的化学发光反应,作为生存能力和呼吸爆发活动的衡量指标。还评估了急性透析液暴露后人间皮细胞白细胞介素(IL)-1 β驱动的IL-8合成。以人血清白蛋白(HSA)为模型蛋白,在5天和20天后测定透析液中晚期糖基化终产物的形成。结果:在所有实验中,Physioneal 35的生物相容性与Physioneal 40亲本制剂相似。在小鼠成纤维细胞实验中,与pH中和的传统乳酸缓冲腹膜透析液相比,Physioneal 35在生物相容性方面表现出显著的改善。在急性暴露试验中,与酸性常规溶液相比,人中性粒细胞活力和呼吸爆发明显改善;然而,间皮细胞没有统计学上的显著改善。AGE的形成被认为是葡萄糖和葡萄糖降解产物引起腹膜结构和功能改变的重要机制,与传统透析液相比,Physioneal 35中AGE的形成明显降低。结论:Physioneal 35的生物相容性与原Physioneal 40碳酸氢盐/乳酸缓冲透析液相似,证实缓冲液含量和钙浓度的差异不影响生物相容性。在体外生物相容性评估中,碳酸氢盐/乳酸制剂(Physioneal 35和Physioneal 40)比传统的乳酸缓冲透析溶液更具生物相容性。
{"title":"The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.","authors":"Line Skoufos,&nbsp;Nicholas Topley,&nbsp;Laurinda Cooker,&nbsp;Anne Dawnay,&nbsp;David J Millar,&nbsp;Clifford J Holmes,&nbsp;Dirk Faict","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Unlabelled: </strong>The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.</p><p><strong>Background: </strong>The biocompatibility profile of a new peritoneal dialysis (PD) solution (Physioneal 35) was determined using a selection of in vitro assay systems. Physioneal 35 is buffered by a combination of 25 mmol/L bicarbonate and 10 mmol/L lactate, thereby providing a solution with a total of 35 mmol/L of alkali to complement the currently available 25 mmol/L bicarbonate and 15 mmol/L lactate combination solution, Physioneal 40. In addition, the new solution contains a calcium concentration of 1.75 mmol/L rather than 1.25 mmol/L present in Physioneal 40. Physioneal 35 and 40 are manufactured in double chamber bag systems that permit separation of glucose from the buffer during sterilization. When the two chambers are mixed just before patient use, the resulting solution has a neutral pH and reduced glucose degradation content. Physioneal 35 was evaluated for its cytotoxicity potential using a murine fibroblast assay, its acute effect on human neutrophil and human peritoneal mesothelial cell function, and its in vitro potential to form advanced glycation end products (AGE). The biocompatibility characteristics of this new formulation were compared with that of a conventional, lactate-based solution and to that of its parent formulation, Physioneal 40.</p><p><strong>Methods: </strong>Proliferation of murine fibroblasts was determined after exposure to dialysis fluids for 72 hours. Cell viability was assayed by the ability to take up neutral red dye. Human neutrophils were exposed for 15 minutes to dialysis fluids, and their ATP content and phorbol 12-myristate 13-acetate (PMA) stimulated chemiluminescence response was determined as a measure of viability and respiratory burst activity, respectively. Cellular interleukin (IL)-1beta-driven IL-8 synthesis by human mesothelial cells following acute exposure to dialysis fluids was also assessed. Advanced glycation end product formation in the dialysis fluids was measured after 5 and 20 days of incubation with human serum albumin (HSA) as the model protein.</p><p><strong>Results: </strong>In all assays employed, the biocompatibility profile of Physioneal 35 was similar to that of the Physioneal 40 parent formulation. Physioneal 35 showed a significant improvement in biocompatibility performance compared to a pH neutralized conventional lactate-buffered peritoneal dialysis solution in the murine fibroblast assay. In the acute exposure assays, human neutrophil viability and respiratory burst were significantly improved compared with the acidic, conventional solution; however, no statistically significant improvement were seen in mesothelial cells. AGE formation, which is thought to be an important mechanism by which glucose and glucose degradation products cause structural and functional changes of the peritoneal membrane, was si","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24304055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proceedings of the Third International Conference on Hypertension and the Kidney, February 2002, Madrid, Spain. 第三届高血压与肾脏国际会议论文集,2002年2月,西班牙马德里。
Pub Date : 2002-12-01
{"title":"Proceedings of the Third International Conference on Hypertension and the Kidney, February 2002, Madrid, Spain.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27543568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. MTHFR基因型和高同型半胱氨酸血症对肾移植受者患者和移植物存活的影响。
Pub Date : 2001-01-01 DOI: 10.1046/j.1523-1755.2001.07854.x
W. Hagen, M. Födinger, G. Heinz, H. Buchmayer, W. Hörl, G. Sunder-Plassmann
BACKGROUND The total homocysteine (tHcy) plasma level, which is partly determined by the MTHFR 677C-->T genotype, may be associated with vascular disease. We prospectively examined the influence of MTHFR genotypes (677C-->T, 1298A-->C) and tHcy plasma concentration on all cause mortality and graft outcomes of renal transplant recipients. METHODS Baseline tHcy plasma levels of 189 patients (three groups with either the MTHFR 677CC, CT or TT genotype, including 63 patients in each group, were matched for age, gender, body mass index and creatinine clearance at baseline), were obtained between September 1996 and May 1997. Follow-up data (time until return to dialysis therapy, time and cause of death) were collected from April to June 1999. Kaplan-Meier survival estimations were calculated and plotted, the groups (three MTHFR 677C-->T genotype groups, or three MTHFR 1298A-->C genotype groups, or two groups with tHcy plasma levels above/below 15 micromol/L) were compared by log-rank test. Age, gender, body mass index (BMI), time since transplantation, serum creatinine, creatinine clearance, combined MTHFR 677C-->T/1298A-->C genotypes, tHcy, folate and vitamin B12 plasma levels were evaluated with regard to graft and patient survival in a multivariate Cox-proportional hazard regression model. RESULTS During the follow-up period of 2.26 +/- 0.66 years, 9 patients died (5 in the TT, 2 in the CT and 2 in the CC genotype group; P = 0.34) and 22 returned to dialysis treatment (7 in the TT, 9 in the CT and 6 in the CC genotype group; P = 0.65). There was also no influence of MTHFR 1298A-->C genotypes (AA genotype, 114 patients; AC genotype, 64 patients; CC genotype, 11 patients) on patient or graft survival (P = 0.7087 and P = 0.1633, respectively). Two of 93 patients with a tHcy plasma level < or = 15 micromol/L died, in contrast to 7 of 96 patients in the tHcy > 15 micromol/L group, P = 0.0778. Two patients in the low tHcy group had to return to dialysis, in contrast to 20 patients in the high tHcy group (P = 0.0001). In the multivariate model there was no significant predictor of patient survival, and the serum creatinine was the only predictor of graft survival (P < 0.0001). CONCLUSIONS In summary, our study shows that neither MTHFR 677C-->T/1298A-->C genotypes nor hyperhomocysteinemia are independently associated with patient or graft survival following kidney transplantation.
总同型半胱氨酸(tHcy)血浆水平部分由MTHFR 677C- >T基因型决定,可能与血管疾病有关。我们前瞻性地研究了MTHFR基因型(677C- >T, 1298A- >C)和tHcy血浆浓度对肾移植受者全因死亡率和移植结果的影响。方法收集1996年9月至1997年5月期间189例患者(MTHFR 677CC、CT或TT基因型三组,每组63例,年龄、性别、体重指数和基线肌酐清除率相匹配)的基线tHcy血浆水平。随访数据(恢复透析治疗的时间、死亡时间和原因)收集于1999年4月至6月。计算和绘制Kaplan-Meier生存估计,通过log-rank检验比较各组(3个MTHFR 677C- >T基因型组,或3个MTHFR 1298A- >C基因型组,或2个tHcy血浆水平高于/低于15微mol/L的组)。年龄、性别、体重指数(BMI)、移植后时间、血清肌酐、肌酐清除率、MTHFR 677C- >T/1298A- >C基因型、tHcy、叶酸和维生素B12血浆水平在多因素cox -比例风险回归模型中与移植物和患者生存相关。结果随访2.26±0.66年,9例患者死亡,其中TT组5例,CT组2例,CC组2例;P = 0.34), 22人恢复透析治疗(TT组7人,CT组9人,CC组6人;P = 0.65)。MTHFR 1298A- >C基因型也无影响(AA基因型114例;AC基因型64例;CC基因型(11例)对患者或移植物存活的影响(P = 0.7087和P = 0.1633)。93例tHcy血浆水平<或= 15微mol/L的患者中有2例死亡,而tHcy > 15微mol/L组96例患者中有7例死亡,P = 0.0778。低tHcy组有2例患者不得不再次透析,而高tHcy组有20例患者不得不再次透析(P = 0.0001)。在多变量模型中,没有显著的患者生存预测因子,血清肌酐是移植物生存的唯一预测因子(P < 0.0001)。总之,我们的研究表明,MTHFR 677C- >T/1298A- >C基因型和高同型半胱氨酸血症与肾移植后患者或移植物存活均无独立相关性。
{"title":"Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients.","authors":"W. Hagen, M. Födinger, G. Heinz, H. Buchmayer, W. Hörl, G. Sunder-Plassmann","doi":"10.1046/j.1523-1755.2001.07854.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07854.x","url":null,"abstract":"BACKGROUND The total homocysteine (tHcy) plasma level, which is partly determined by the MTHFR 677C-->T genotype, may be associated with vascular disease. We prospectively examined the influence of MTHFR genotypes (677C-->T, 1298A-->C) and tHcy plasma concentration on all cause mortality and graft outcomes of renal transplant recipients. METHODS Baseline tHcy plasma levels of 189 patients (three groups with either the MTHFR 677CC, CT or TT genotype, including 63 patients in each group, were matched for age, gender, body mass index and creatinine clearance at baseline), were obtained between September 1996 and May 1997. Follow-up data (time until return to dialysis therapy, time and cause of death) were collected from April to June 1999. Kaplan-Meier survival estimations were calculated and plotted, the groups (three MTHFR 677C-->T genotype groups, or three MTHFR 1298A-->C genotype groups, or two groups with tHcy plasma levels above/below 15 micromol/L) were compared by log-rank test. Age, gender, body mass index (BMI), time since transplantation, serum creatinine, creatinine clearance, combined MTHFR 677C-->T/1298A-->C genotypes, tHcy, folate and vitamin B12 plasma levels were evaluated with regard to graft and patient survival in a multivariate Cox-proportional hazard regression model. RESULTS During the follow-up period of 2.26 +/- 0.66 years, 9 patients died (5 in the TT, 2 in the CT and 2 in the CC genotype group; P = 0.34) and 22 returned to dialysis treatment (7 in the TT, 9 in the CT and 6 in the CC genotype group; P = 0.65). There was also no influence of MTHFR 1298A-->C genotypes (AA genotype, 114 patients; AC genotype, 64 patients; CC genotype, 11 patients) on patient or graft survival (P = 0.7087 and P = 0.1633, respectively). Two of 93 patients with a tHcy plasma level < or = 15 micromol/L died, in contrast to 7 of 96 patients in the tHcy > 15 micromol/L group, P = 0.0778. Two patients in the low tHcy group had to return to dialysis, in contrast to 20 patients in the high tHcy group (P = 0.0001). In the multivariate model there was no significant predictor of patient survival, and the serum creatinine was the only predictor of graft survival (P < 0.0001). CONCLUSIONS In summary, our study shows that neither MTHFR 677C-->T/1298A-->C genotypes nor hyperhomocysteinemia are independently associated with patient or graft survival following kidney transplantation.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78261757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. 一氧化氮在n -甲基- d -天冬氨酸受体活化剂胍丁二酸合成中的作用。
Pub Date : 2001-01-01 DOI: 10.1046/j.1523-1755.2001.07842.x
K. Aoyagi, S. Shahrzad, S. Iida, C. Tomida, A. Hirayama, S. Nagase, K. Takemura, A. Koyama, S. Ohba, M. Narita, B. Cohen
BACKGROUND We propose that reactive oxygen and argininosuccinic acid (ASA) form guanidinosuccinic acid (GSA). An alternative to this hypothesis is the so-called guanidine cycle, which consists of a series of hydroxyurea derivatives that serve as intermediates in a pathway leading from urea to GSA. We compare the role of the guanidine cycle to that of nitric oxide (NO) in the synthesis of GSA. METHODS The members of the guanidine cycle (hydroxyurea, hydroxylamine plus homoserine, L-canaline, and L-canavanine) were incubated with isolated rat hepatocytes. The known NO donors, NOR-2, NOC-7, and SIN-1, were incubated with ASA in vitro. Ornithine, arginine, or citrulline, which increase arginine, a precursor of NO, were incubated with isolated rat hepatocytes. GSA was determined by high-performance liquid chromatography. RESULTS None of guanidine cycle members except for urea formed GSA. SIN-1, which generates superoxide and NO formed GSA, but other simple NO donors, did not. Both carboxy-PTIO, a scavenger of NO, and dimethyl sulfoxide, a hydroxyl radical scavenger, completely inhibited GSA synthesis by SIN-1. GSA formation by SIN-1 reached a maximum at 0.5 mmol/L and decreased at higher concentrations. GSA synthesis, stimulated by urea in isolated hepatocytes, was inhibited by ornithine, arginine, or citrulline with ammonia, but not by ornithine without ammonia, where arginine production is limited. CONCLUSION GSA is formed from ASA and the hydroxyl radical. When arginine increased in hepatocytes, GSA synthesis decreased. These data suggest that increased NO, which results from high concentrations of arginine, or SIN-1 scavenges the hydroxyl radical. This may explain the decreased GSA synthesis in inborn errors of the urea cycle where ASA is decreased, and also the diminished GSA excretion in arginemia.
我们提出活性氧和精氨酸琥珀酸(ASA)形成胍丁二酸(GSA)。这一假设的另一种选择是所谓的胍循环,它由一系列羟基脲衍生物组成,作为从尿素到GSA的途径的中间体。我们比较了胍循环和一氧化氮(NO)在GSA合成中的作用。方法用离体大鼠肝细胞孵育胍环的成员(羟基脲、羟胺加同型丝氨酸、l -犬碱和l -犬碱)。已知NO供体NO -2、NOC-7和SIN-1用ASA体外孵育。鸟氨酸、精氨酸或瓜氨酸能增加精氨酸(一氧化氮的前体),与分离的大鼠肝细胞孵育。采用高效液相色谱法测定GSA。结果除尿素外,所有胍环成员均不形成GSA。生成超氧化物和一氧化氮的SIN-1形成了GSA,但其他简单的一氧化氮供体却没有。羧基ptio (NO的清除剂)和二甲基亚砜(羟基自由基的清除剂)都能完全抑制SIN-1合成GSA。在0.5 mmol/L时,SIN-1的GSA生成量最大,浓度越高,GSA生成量越低。在分离的肝细胞中,尿素刺激GSA的合成,被鸟氨酸、精氨酸或瓜氨酸加氨抑制,但不加氨的鸟氨酸不抑制GSA的合成,因为精氨酸的产生有限。结论sa是由ASA和羟基自由基形成的。当精氨酸在肝细胞中增加时,GSA的合成减少。这些数据表明,高浓度精氨酸或SIN-1引起的一氧化氮增加可以清除羟基自由基。这可能解释了先天性尿素循环错误中GSA合成减少的原因,也解释了精氨酸血症中GSA排泄减少的原因。
{"title":"Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.","authors":"K. Aoyagi, S. Shahrzad, S. Iida, C. Tomida, A. Hirayama, S. Nagase, K. Takemura, A. Koyama, S. Ohba, M. Narita, B. Cohen","doi":"10.1046/j.1523-1755.2001.07842.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07842.x","url":null,"abstract":"BACKGROUND We propose that reactive oxygen and argininosuccinic acid (ASA) form guanidinosuccinic acid (GSA). An alternative to this hypothesis is the so-called guanidine cycle, which consists of a series of hydroxyurea derivatives that serve as intermediates in a pathway leading from urea to GSA. We compare the role of the guanidine cycle to that of nitric oxide (NO) in the synthesis of GSA. METHODS The members of the guanidine cycle (hydroxyurea, hydroxylamine plus homoserine, L-canaline, and L-canavanine) were incubated with isolated rat hepatocytes. The known NO donors, NOR-2, NOC-7, and SIN-1, were incubated with ASA in vitro. Ornithine, arginine, or citrulline, which increase arginine, a precursor of NO, were incubated with isolated rat hepatocytes. GSA was determined by high-performance liquid chromatography. RESULTS None of guanidine cycle members except for urea formed GSA. SIN-1, which generates superoxide and NO formed GSA, but other simple NO donors, did not. Both carboxy-PTIO, a scavenger of NO, and dimethyl sulfoxide, a hydroxyl radical scavenger, completely inhibited GSA synthesis by SIN-1. GSA formation by SIN-1 reached a maximum at 0.5 mmol/L and decreased at higher concentrations. GSA synthesis, stimulated by urea in isolated hepatocytes, was inhibited by ornithine, arginine, or citrulline with ammonia, but not by ornithine without ammonia, where arginine production is limited. CONCLUSION GSA is formed from ASA and the hydroxyl radical. When arginine increased in hepatocytes, GSA synthesis decreased. These data suggest that increased NO, which results from high concentrations of arginine, or SIN-1 scavenges the hydroxyl radical. This may explain the decreased GSA synthesis in inborn errors of the urea cycle where ASA is decreased, and also the diminished GSA excretion in arginemia.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75972010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells. 透析膜对单核细胞白细胞介素-1 β (il -1 β)和il -1 β转化酶的影响。
Pub Date : 2001-01-01 DOI: 10.1046/j.1523-1755.2001.07829.x
S. Linnenweber, G. Lonnemann
BACKGROUND In vitro stimulation of mononuclear cells (peripheral blood mononuclear cells; PBMCs) with an endotoxin (lipopolysaccharide; LPS) revealed elevated cell-associated levels of interleukin-1beta (IL-1beta) in end-stage renal disease (ESRD) patients on Cuprophan hemodialysis (HD), suggesting a defect in the process of IL-1beta's release from activated cells. IL-1beta is initially synthesized as an inactive precursor called proIL-1beta. ProIL-1beta is processed into the biologically active mature form of IL-1beta (mIL-1beta) requiring the specific IL-1beta-converting enzyme (ICE). METHODS Using specific immunoassays (enzyme-linked immunosorbent assays), we measured cell-associated and extracellular proIL-1beta as well as mIL-1beta in LPS-stimulated PBMCs to test whether ICE-dependent processing of proIL-1beta and/or secretion of mIL-1beta was impaired in ESRD patients compared with healthy controls. PBMCs of healthy controls (N = 9), of ESRD patients on peritoneal dialysis (PD, N = 10), and of those patients on intermittent HD (N = 8) were studied. The same HD patients were studied three times with low-flux Cuprophan (GFS 12), low-flux polysulfon (F6 HPS), and high-flux polysulfon (F60S) in randomized order. PBMCs were separated from whole blood by Ficoll-Hypaque centrifugation and incubated in vitro for 18 hours in the presence LPS (10 ng/mL). Extracellular (PBMC culture supernatants) and cell-associated (cell lysates) levels of proIL-1beta and mIL-1beta were measured. RESULTS The total production (cell-associated plus extracellular) of LPS-induced IL-1beta (proIL-1beta plus mIL-1beta) was similar in healthy controls (25.96 +/- 0.84 ng/2.5 x 10(6) PBMC), PD patients (29.53 +/- 1.31 ng/2.5 x 106 PBMC), and in Cuprophan-treated HD patients (23.28 +/- 1.24 ng/2.5 x 10(6) PBMC). In normal controls, 43.6% of the total IL-1beta was processed into mIL-1beta, which was significantly more than that in PD patients (27.3%, P < 0.02) but was similar to that in Cuprophan-treated HD patients (37.1%). Comparing cell-associated and extracellular concentrations of mIL-1beta, PBMCs of normal controls secreted 82.2% of mIL-1beta; this was significantly more than that in PD patients (59.4%, P < 0.01) and that in Cuprophan HD patients (54.2%, P < 0.01). When HD patients were switched from Cuprophan to F6 HPS or F60S, neither total IL-1beta production nor processing of IL-1beta changed. However, secretion of mIL-1beta increased significantly with F6 HPS (80.6%, P < 0.01) as well as with F60S (76.6%, P < 0.02) compared with Cuprophan. CONCLUSION We conclude that the ability of PBMCs to produce IL-1beta in response to LPS is normal in PD patients as well as in HD patients. ICE-dependent processing of inactive proIL-1beta into biologically active mIL-1beta is reduced in PD patients, but not in HD patients. Secretion of mIL-1beta is impaired in PD and HD patients treated with Cuprophan. This impaired ability to secrete active mIL-1beta seems to be independent
背景:体外刺激单核细胞(外周血单核细胞;含有内毒素(脂多糖;脂多糖(LPS)显示,终末期肾病(ESRD)患者库泊芬血液透析(HD)中白细胞介素-1 β (il -1 β)细胞相关水平升高,提示il -1 β从活化细胞释放的过程中存在缺陷。il -1最初是作为一种非活性前体合成的,称为proil -1 β。proil -1 β被加工成具有生物活性的成熟形式的il -1 β (mil -1 β),需要特异性的il -1 β转换酶(ICE)。方法采用特异性免疫测定法(酶联免疫吸附测定法),我们测量了lps刺激的PBMCs中细胞相关和细胞外的proil -1 β以及mil -1 β,以测试ESRD患者与健康对照组相比,ice依赖的proil -1 β加工和/或mil -1 β分泌是否受损。研究了健康对照组(N = 9)、接受腹膜透析的ESRD患者(N = 10)和间歇性HD患者(N = 8)的PBMCs。同样的HD患者被随机分为三组,分别使用低通量库泊芬(GFS 12)、低通量聚砜(F6 HPS)和高通量聚砜(F60S)。采用Ficoll-Hypaque离心法从全血中分离PBMCs,在LPS (10 ng/mL)存在下体外培养18小时。测定细胞外(PBMC培养上清液)和细胞相关(细胞裂解液)的proil -1 β和mil -1 β水平。结果lps诱导的il -1 β (proil -1 β + mil -1 β)的总生成(细胞相关和细胞外)在健康对照组(25.96 +/- 0.84 ng/2.5 × 10(6) PBMC)、PD患者(29.53 +/- 1.31 ng/2.5 × 106 PBMC)和库泊芬治疗的HD患者(23.28 +/- 1.24 ng/2.5 × 10(6) PBMC)中相似。在正常对照组中,总il -1 β的43.6%被加工成mil -1 β,显著高于PD患者(27.3%,P < 0.02),但与库洛芬治疗的HD患者(37.1%)相似。比较mil -1 β的细胞相关浓度和细胞外浓度,正常对照的pbmc分泌82.2%的mil -1 β;明显高于PD组(59.4%,P < 0.01)和库泊芬HD组(54.2%,P < 0.01)。当HD患者从库泊芬切换到F6 HPS或F60S时,il -1 β的总生成和il -1 β的加工都没有改变。F6 HPS组mil -1 β的分泌量(80.6%,P < 0.01)和F60S组mil -1 β的分泌量(76.6%,P < 0.02)显著高于cuphaan组。结论:在PD患者和HD患者中,PBMCs响应LPS产生il -1 β的能力是正常的。非活性proil -1 β转化为生物活性mil -1 β的ice依赖性加工在PD患者中减少,但在HD患者中没有减少。使用库泊芬治疗的PD和HD患者mil -1 β分泌受损。这种分泌活性mil -1 β的能力受损似乎与ICE活性无关,当hd患者从库泊芬切换到低通量或高通量聚砜时,这种能力恢复正常。循环PBMCs中与细胞相关的生物活性mil -1 β水平升高代表了一种炎症状态,可能导致慢性炎症性疾病,如β -微球蛋白淀粉样变性。合成膜替代库泊芬可使ESRD患者的PBMC功能正常化并减少炎症状态。
{"title":"Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells.","authors":"S. Linnenweber, G. Lonnemann","doi":"10.1046/j.1523-1755.2001.07829.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07829.x","url":null,"abstract":"BACKGROUND In vitro stimulation of mononuclear cells (peripheral blood mononuclear cells; PBMCs) with an endotoxin (lipopolysaccharide; LPS) revealed elevated cell-associated levels of interleukin-1beta (IL-1beta) in end-stage renal disease (ESRD) patients on Cuprophan hemodialysis (HD), suggesting a defect in the process of IL-1beta's release from activated cells. IL-1beta is initially synthesized as an inactive precursor called proIL-1beta. ProIL-1beta is processed into the biologically active mature form of IL-1beta (mIL-1beta) requiring the specific IL-1beta-converting enzyme (ICE). METHODS Using specific immunoassays (enzyme-linked immunosorbent assays), we measured cell-associated and extracellular proIL-1beta as well as mIL-1beta in LPS-stimulated PBMCs to test whether ICE-dependent processing of proIL-1beta and/or secretion of mIL-1beta was impaired in ESRD patients compared with healthy controls. PBMCs of healthy controls (N = 9), of ESRD patients on peritoneal dialysis (PD, N = 10), and of those patients on intermittent HD (N = 8) were studied. The same HD patients were studied three times with low-flux Cuprophan (GFS 12), low-flux polysulfon (F6 HPS), and high-flux polysulfon (F60S) in randomized order. PBMCs were separated from whole blood by Ficoll-Hypaque centrifugation and incubated in vitro for 18 hours in the presence LPS (10 ng/mL). Extracellular (PBMC culture supernatants) and cell-associated (cell lysates) levels of proIL-1beta and mIL-1beta were measured. RESULTS The total production (cell-associated plus extracellular) of LPS-induced IL-1beta (proIL-1beta plus mIL-1beta) was similar in healthy controls (25.96 +/- 0.84 ng/2.5 x 10(6) PBMC), PD patients (29.53 +/- 1.31 ng/2.5 x 106 PBMC), and in Cuprophan-treated HD patients (23.28 +/- 1.24 ng/2.5 x 10(6) PBMC). In normal controls, 43.6% of the total IL-1beta was processed into mIL-1beta, which was significantly more than that in PD patients (27.3%, P < 0.02) but was similar to that in Cuprophan-treated HD patients (37.1%). Comparing cell-associated and extracellular concentrations of mIL-1beta, PBMCs of normal controls secreted 82.2% of mIL-1beta; this was significantly more than that in PD patients (59.4%, P < 0.01) and that in Cuprophan HD patients (54.2%, P < 0.01). When HD patients were switched from Cuprophan to F6 HPS or F60S, neither total IL-1beta production nor processing of IL-1beta changed. However, secretion of mIL-1beta increased significantly with F6 HPS (80.6%, P < 0.01) as well as with F60S (76.6%, P < 0.02) compared with Cuprophan. CONCLUSION We conclude that the ability of PBMCs to produce IL-1beta in response to LPS is normal in PD patients as well as in HD patients. ICE-dependent processing of inactive proIL-1beta into biologically active mIL-1beta is reduced in PD patients, but not in HD patients. Secretion of mIL-1beta is impaired in PD and HD patients treated with Cuprophan. This impaired ability to secrete active mIL-1beta seems to be independent","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91469173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
beta2-microglobulin-derived amyloidosis: an update. β -微球蛋白衍生淀粉样变性:最新进展。
Pub Date : 2001-01-01 DOI: 10.1046/j.1523-1755.2001.07823.x
Jürgen Floege, Markus Ketteler
The present review attempts to summarize recent developments in the field of beta2-microglobulin-derived amyloidosis (A(beta2)m amyloidosis) in patients on chronic dialysis therapy. A key factor in the pathogenesis is the uremic retention of the precursor molecule, beta2-microglobulin (beta2m). However, secondary modifications of the molecule such as limited proteolysis, conformational changes, and the formation of advanced glycation end products have also been described. Finally, in order to explain the striking predilection of the disease for synovial and periarticular structures, a role of local predisposing factors within the synovial membrane (for example, of the particular constituents of the extracellular matrix) must also be postulated. With respect to clinical symptomatology, recent data have confirmed that clinically manifest signs of the amyloidosis represent only the tip of the iceberg, since histologically amyloid deposition is much more widespread. Noninvasive diagnosing of the disease has been advanced by technical changes of the beta2m scintigraphy. Finally, there is accumulating evidence that prevention of the disease not only includes the usage of high-flux synthetic membranes for hemodialysis or hemodiafiltration, but that other factors contribute to the clinical manifestations of amyloidosis such as the dialysate composition and its microbacteriological quality. Such factors, which have changed over the last years as part of general improvements in dialysis care, may explain why the prevalence of the amyloidosis appears to decrease.
本文综述了慢性透析治疗患者β 2-微球蛋白衍生淀粉样变性(A(β 2)m淀粉样变性)领域的最新进展。发病机制的一个关键因素是前体分子β -微球蛋白(β - 2m)的尿毒症潴留。然而,分子的二次修饰,如有限的蛋白质水解、构象变化和晚期糖基化终产物的形成也被描述过。最后,为了解释滑膜和关节周围结构对该疾病的惊人偏好,还必须假设滑膜内局部易感因素(例如,细胞外基质的特定成分)的作用。关于临床症状,最近的资料证实,淀粉样变的临床表现只是冰山一角,因为组织学上淀粉样蛋白沉积更为广泛。由于β - 2显像技术的进步,这种疾病的无创诊断已经取得了进展。最后,越来越多的证据表明,预防该疾病不仅包括使用高通量合成膜进行血液透析或血液透析滤过,而且其他因素也有助于淀粉样变的临床表现,如透析液组成及其微生物学质量。这些因素在过去几年中随着透析护理的普遍改善而发生了变化,这可能解释了淀粉样变的患病率似乎有所下降的原因。
{"title":"beta2-microglobulin-derived amyloidosis: an update.","authors":"Jürgen Floege, Markus Ketteler","doi":"10.1046/j.1523-1755.2001.07823.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07823.x","url":null,"abstract":"The present review attempts to summarize recent developments in the field of beta2-microglobulin-derived amyloidosis (A(beta2)m amyloidosis) in patients on chronic dialysis therapy. A key factor in the pathogenesis is the uremic retention of the precursor molecule, beta2-microglobulin (beta2m). However, secondary modifications of the molecule such as limited proteolysis, conformational changes, and the formation of advanced glycation end products have also been described. Finally, in order to explain the striking predilection of the disease for synovial and periarticular structures, a role of local predisposing factors within the synovial membrane (for example, of the particular constituents of the extracellular matrix) must also be postulated. With respect to clinical symptomatology, recent data have confirmed that clinically manifest signs of the amyloidosis represent only the tip of the iceberg, since histologically amyloid deposition is much more widespread. Noninvasive diagnosing of the disease has been advanced by technical changes of the beta2m scintigraphy. Finally, there is accumulating evidence that prevention of the disease not only includes the usage of high-flux synthetic membranes for hemodialysis or hemodiafiltration, but that other factors contribute to the clinical manifestations of amyloidosis such as the dialysate composition and its microbacteriological quality. Such factors, which have changed over the last years as part of general improvements in dialysis care, may explain why the prevalence of the amyloidosis appears to decrease.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89365690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 54
Apoptosis and extracellular matrix-cell interactions in kidney disease. 肾脏疾病中的细胞凋亡和细胞外基质-细胞相互作用。
Pub Date : 2000-09-01
H Makino, H Sugiyama, N Kashihara

Apoptosis and extracellular matrix-cell interactions in kidney disease. Extracellular matrix (ECM)-cell interactions have major effects on phenotypic features such as cell growth, differentiation, and gene expression. Apoptosis is an active form of cell death that is crucial for maintaining an appropriate number of cells as well as tissue organization. Recent reports have implied that ECM can influence survival and apoptosis of several cell lineages including glomerular mesangial cells (MC). Numerous glomerular diseases are associated with the expansion of the mesangial ECM, which may eventually produce glomerular scarring. Glomerular cell apoptosis is associated with the deletion of glomerular cells and the accumulation of ECM in the progression of glomerulosclerosis in rat remnant kidney model induced by 5/6 nephrectomy. Our recent study indicated that basement membrane matrix (a model for normal ECM components) prevented cultured MC from undergoing apoptosis after serum deprivation, thus promoting their survival, compared with type I collagen matrix (a model for abnormal ECM components). Inhibition of matrix-derived signals by antisense oligonucleotides against beta1 integrin increased MC apoptosis. Data suggest that the survival and death of MC are regulated by the surrounding ECM through integrin molecules. The mechanism of regulation of MC apoptosis by ECM requires further in vivo study to gain new insight into the treatment of glomerular diseases as well as the pathophysiology of the mesangium. Diabetic nephropathy is characterized by the abnormal ECM accumulation and the phenotypic change of MC. Some speculations on the possible involvement of apoptosis in diabetic nephropathy are also discussed.

肾脏疾病中的细胞凋亡和细胞外基质-细胞相互作用。细胞外基质(ECM)-细胞相互作用对细胞生长、分化和基因表达等表型特征有重要影响。细胞凋亡是一种活跃的细胞死亡形式,对于维持适当数量的细胞和组织至关重要。最近的报道表明,ECM可以影响包括肾小球系膜细胞(MC)在内的几种细胞系的存活和凋亡。许多肾小球疾病与系膜外膜的扩张有关,最终可能导致肾小球瘢痕形成。5/6肾切除术大鼠残肾模型肾小球硬化过程中,肾小球细胞凋亡与肾小球细胞缺失和ECM积累有关。我们最近的研究表明,与I型胶原基质(异常ECM成分模型)相比,基底膜基质(正常ECM成分模型)可以阻止培养的MC在血清剥夺后发生凋亡,从而促进其存活。对β 1整合素的反义寡核苷酸对基质来源信号的抑制增加了MC细胞凋亡。数据表明,MC的生存和死亡受周围ECM通过整合素分子调控。ECM调控MC细胞凋亡的机制需要进一步的体内研究,为肾小球疾病的治疗以及系膜的病理生理提供新的认识。糖尿病肾病以异常的ECM积累和MC的表型改变为特征,并对细胞凋亡在糖尿病肾病中可能参与的一些推测进行了讨论。
{"title":"Apoptosis and extracellular matrix-cell interactions in kidney disease.","authors":"H Makino,&nbsp;H Sugiyama,&nbsp;N Kashihara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Apoptosis and extracellular matrix-cell interactions in kidney disease. Extracellular matrix (ECM)-cell interactions have major effects on phenotypic features such as cell growth, differentiation, and gene expression. Apoptosis is an active form of cell death that is crucial for maintaining an appropriate number of cells as well as tissue organization. Recent reports have implied that ECM can influence survival and apoptosis of several cell lineages including glomerular mesangial cells (MC). Numerous glomerular diseases are associated with the expansion of the mesangial ECM, which may eventually produce glomerular scarring. Glomerular cell apoptosis is associated with the deletion of glomerular cells and the accumulation of ECM in the progression of glomerulosclerosis in rat remnant kidney model induced by 5/6 nephrectomy. Our recent study indicated that basement membrane matrix (a model for normal ECM components) prevented cultured MC from undergoing apoptosis after serum deprivation, thus promoting their survival, compared with type I collagen matrix (a model for abnormal ECM components). Inhibition of matrix-derived signals by antisense oligonucleotides against beta1 integrin increased MC apoptosis. Data suggest that the survival and death of MC are regulated by the surrounding ECM through integrin molecules. The mechanism of regulation of MC apoptosis by ECM requires further in vivo study to gain new insight into the treatment of glomerular diseases as well as the pathophysiology of the mesangium. Diabetic nephropathy is characterized by the abnormal ECM accumulation and the phenotypic change of MC. Some speculations on the possible involvement of apoptosis in diabetic nephropathy are also discussed.</p>","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21830488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney international. Supplement
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1